Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary
disease with a median survival of 2–4 years after diagnosis. A significant number of IPF …

Background Ever since a lung cancer epidemic emerged in the mid-1900s, the
epidemiology of lung cancer has been intensively investigated to characterize its causes …

Bleomycin (BLM) is a drug used to treat different types of neoplasms. BLM's most severe
adverse effect is lung toxicity, which induces remodeling of lung architecture and loss of …

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with an estimated
median survival time of 3–5 years after diagnosis. This condition occurs primarily in elderly …

Introduction Comorbidities significantly influence the clinical course of idiopathic pulmonary
fibrosis (IPF). However, their prognostic impact is not fully understood. We therefore aimed to …

BACKGROUND Lung cancer (LC) is frequently associated with idiopathic pulmonary fibrosis
(IPF). Despite this well-known association, the outcome of LC in patients with IPF is unclear …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease (ILD) of unknown aetiology, with a median survival of 2–4 years from the time of …

Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive
fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, and …

Background Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease implicated as an
independent risk factor for lung cancer. However, optimal treatment for advanced lung …

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease of unknown etiology.
With a gradually increasing worldwide prevalence and a mortality rate exceeding that of …